Evidence map›Paper›PMID 32953848›Full record

ArticleWorld journal of clinical cases2020

Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer.

Sung Yong Han, Dong Uk Kim, Young Mi Seol, Suk Kim, Nam Kyung Lee, Seung Baek Hong, Hyung-Il Seo

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of clinical cases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sung Yong HanDepartment of Internal Medicine and Biomedical Research Institute, Division of Gastroenterology, Pusan National University Hospital, Busan 49241, South Korea.
Dong Uk KimDepartment of Internal Medicine and Biomedical Research Institute, Division of Gastroenterology, Pusan National University Hospital, Busan 49241, South Korea. amlm3@hanmail.net.
Young Mi SeolDepartment of Hematology-Oncology, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea.
Suk KimDepartment of Radiology, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea.
Nam Kyung LeeDepartment of Radiology, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea.
Seung Baek HongDepartment of Radiology, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea.
Hyung-Il SeoDepartment of Surgery, Biomedical Research Institute, Pusan National University Hospital, Busan 49241, South Korea.
Pusan National University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious.

aimTo evaluate a retrospective analysis comparing the efficacy and safety of FFX and GA as first-line chemotherapeutic regimens in patients with metastatic pancreatic cancer.

methodsWe retrospectively analyzed and compared outcomes in 101 patients who presented with pancreatic cancer and were treated with either GA (

resultsThere were no significant differences between two groups in baseline characteristics, except for the ECOG performance status. The median progression-free survival (PFS) (6.43 mo

conclusionGA regimen may be recommended to the patients with NLR < 3 or ECOG 0 status although GA and FFX showed comparable efficacy outcomes in patients with metastatic pancreatic cancer.

Indexed as

Adverse eventChemotherapyFOLFIRINOXMetastatic pancreatic carcinomaNab-paclitaxel plus gemcitabinePredict marker

Identifiers

PMID32953848
PMCPMC7479547
OpenAlexW3082996504

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.